<DOC>
	<DOCNO>NCT02876510</DOCNO>
	<brief_summary>The ACTolog clinical trial IMA101-101 first-in-human trial ACTolog concept target patient advanced stage solid cancer depend expression ACTolog target within tumor . In IMA101-101 trial , patient 's tumor first biomarker test expression ACTolog target ( `` antigen warehouse '' ) . Only individual tumor positive least one ACTolog target , patient enrol trial .</brief_summary>
	<brief_title>ACTolog Patients With Solid Cancers</brief_title>
	<detailed_description>Within IMA101-101 study patient relapse and/or refractory solid cancer treat autologous CD8+ T-cell product ( IMA101 ) specific novel target ACTolog warehouse identify XPRESIDENT target discovery platform . During production autologous T-cell product patient receive line establish treatment . If last establish therapy option longer warrant ( e.g . disease progression ) , IMA101 T-cell product administer patient lymphodepleting pre-conditioning non-myeloablative chemotherapy ( Flu/CY ) . Low-dose IL-2 give thereafter 14 day enhance T-cell persistence .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients must pathologically confirm advanced/metastatic cancer prior enrollment . 2 . HLA phenotype HLAA*02:01 prior enrollment . 3 . Age : ≥18 year ≤65 year ( select patient sufficient proliferative capacity T cell ) . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 5 . Life expectancy &gt; 6 month prior enrollment . 6 . Patient candidate maximum one line establish therapy ( prior treatment ACTolog ) . Additional inclusion criterion per protocol . 1 . Any condition contraindicate leukapheresis . 2 . Patients brain metastasis . 3 . HIV infection , active Hepatitis B C infection , active infection require oral intravenous antibiotic cause severe disease pose severe danger lab personnel work patient ' blood tissue . If positive test result indicative active infection , patient include . 4 . For active therapeutic part protocol ( treatment phase treatment observation phase ) : concomitant therapy indicate follow : interferon nonstudy immunotherapy regimen ; cytotoxic chemotherapy ( lymphodepleting regimen accord protocol allow ) ; immunosuppressive agent ; investigational therapy ; chronic use systemic corticosteroid ( long steroid dose significantly great require physiologic replacement ) . 5 . Previous extensive radiotherapy lung liver last 4 month prior lymphodepletion regimen . 6 . The patient cardiac condition follow : uncontrolled hypertension ( BP &gt; 150/100 ) despite optimal therapy , uncontrolled angina , ventricular arrhythmia , congestive heart failure ( New York Heart Association Class II ) , baseline LVEF ≤ 50 % , prior current cardiomyopathy , atrial fibrillation heart rate &gt; 100 bpm , unstable ischemic heart disease ( myocardial infarction within 6 month prior start treatment angina require use nitrate weekly ) . 7 . Patients prior stem cell transplantation solid organ transplantation . 8 . The patient concurrent severe and/or uncontrolled medical disease could compromise participation study ( i.e. , uncontrolled diabetes , severe infection require active treatment , severe malnutrition , chronic severe liver renal disease ) . 9 . Active diverticulitis , intraabdominal abscess , gastrointestinal obstruction , abdominal carcinomatosis know risk factor bowel perforation . 10 . History malignancy ( except adequately treat basal squamous cell carcinoma carcinoma situ ) within last 5 year . 11 . The patient pregnant ( confirm serum bHCG , applicable ) breastfeeding . 12 . Serious autoimmune disease discretion treat attending : Patients history active serious inflammatory bowel disease ( include Crohn 's disease ulcerative colitis ) autoimmune disorder rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic Lupus Erythematosus autoimmune vasculitis [ e.g . Wegener 's Granulomatosis ] exclude study . 13 . History hypersensitivity cyclophosphamide , fludarabine IL2 . 14 . Immunosuppression , related prior treatment malignancy . 15 . History current immunodeficiency disease prior treatment compromise immune function discretion treat physician . 16 . Any condition would , investigator 's judgment , contraindicate patient 's participation clinical study due safety concern compliance clinical study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Head neck squamous cell carcinoma</keyword>
	<keyword>Squamous non-small cell lung cancer</keyword>
</DOC>